47 results about "Diabetic Vascular Complications" patented technology

The present invention discloses an application of a double-sugar chain hederin compound in preparation of a drug for preventing vascular endothelial cell inflammatory injury. The compound can alleviate the vascular endothelial cell inflammatory injury by directly inhibiting adsorption of inflammatory factors and adhesion molecules, and regulating a NF-kappa-B signaling pathway and other various pathways, and plays a protection function of the vascular endothelial cell inflammatory injury. The application of the double-sugar chain hederin in the preparation of the drug for preventing the vascular endothelial cell inflammatory injury s is first disclosed, and the double-sugar chain hederin compound is rich in raw material source and mature in preparation method, and has good value in development of drugs for treating vascular endothelial cell inflammatory injury related acute lung injury, kidney injury, pyohemia, atherosclerosis, vascular complications of diabetes, etc.

The invention provides a preparation method of cinchonain Ib. In the method, alcohol extracts of roots, fruits, stems and/or leaves of rosaceous plants, vitaceous vitis plants and smilacaceous plants are used as raw materials, and the raw materials are subjected to multiple liquid chromatographic enrichment and refining to obtain high-purity cinchonain Ib. The invention also provides application of cinchonain Ib in the preparation of drugs for preventing and treating diabetics or diabetic vascular complications, and a pharmaceutical composition comprising cinchonain Ib. The cinchonain Ib has the effect of lowering blood lipid in diabetic rats, has good synergy in controlling the progress of diabetic vascular complications, helps prevent and control metabolic syndromes so that the cinchonain Ib is more significantly advantageous in preventing and treating diabetic vascular complications, is efficient and nontoxic and high in safety and accordingly has a promising application prospect in the clinical prevention and treatment of diabetic vascular complications.

The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification. The invention also discloses, method for preparation of the novel compounds of the series and pharmaceutical composition having one or more compounds as defined above as active ingredients. The invention further discloses a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.

The invention relates to the new application field of composition of red yeast rice and ginkgo leaves in the aspect of controlling diabetic complications, belonging to the fields of medicines and health foods. In order to solve the technical problems, the invention provides the application of the composition of red yeast rice and ginkgo leaves in the aspect of controlling diabetic complications. The composition of red yeast rice and ginkgo leaves has remarkable effects in controlling diabetic complications such as dyslipidemia, diabetic vascular complications, diabetic cardio-cerebrovascular diseases and diabet acompanied by coronary heart disease.

The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species with an alcohol-based solvent in the presence of an acetic acid solution to form an extract composition, (b) subjecting a resultant product obtained in step (a) to obtain a soluble fraction, and (c) removing solvent from the soluble fraction obtained in step (b) to obtain the extract product.

The present invention discloses an application of gentiopicroside to the preparation of medicines for lowering blood sugar and/or improving diabetic vascular complications, and an application of gentiopicroside to the preparation of medicines for reducing blood fat. The invention also discloses a method for extracting gentiopicroside. The invention proves that gentiopicroside can obviously reduceglycometabolism indexes such as blood sugar, glycosylated hemoglobin and serum protein of diabetic model mice, regulate the abnormality of blood fat and oxidative stress index of the model mice, and obviously improve the abnormality of renal function, renal tissue pathology and inflammatory fibrosis components of the model mice. Moreover, the gentiopicroside has good effect on improving LDL-C and24-hour urine protein. Consequently, the gentiopicroside is a traditional Chinese medicine monomer medicament which has the potential of reducing blood sugar and comprehensively improving diabetic nephropathy.

The invention relates to an application of a rhein-arginine complex in the preparation of medicines for treating diabetic nephropathies. The medicines for treating diabetic nephropathies are medicines for improving tiny amounts of proteinuria, creatinine and non-protein nitrogen. The medicines are novel medicines having a good safety, have better medicine effects than traditional treatment medicines and treatment methods, and allow the examples of a traditional Chinese medicinal super-molecule technology in the reconstruction of important effective components to be started and the researches and applications of the super-molecule technology in traditional Chinese medicines innovated medicines to be enlarged. The rhein-arginine complex is called rhein-arginine for short, is a new crystalline compound, and releases rhein and arginine after the rhein-arginine enters a body; and the dissolvability of rhein is changed, and the bioavailability is improved; the stability is good; a rhein parent compound is endowed with a new structural characteristic; and the rhein-arginine can inhibit a plurality of inflammatory factors comprising NFkappaB, TNFalpha, ROS, EGF and the like, can regulate the endothelin system and can improve endothelial cells.